The diabetes treatment developer will target at least $400m from a Hong Kong offering that will allow WuXi PharmaTech to exit.
Hua Medicine, a diabetes treatment developer backed by pharmaceutical company WuXi PharmaTech, intends to raise upwards of $400m in an initial public offering, Reuters reported today.
Goldman Sachs will be lead underwriter for the offering, which would take place on the Hong Kong Stock Exchange in the second half of 2018, according to people with knowledge of the matter. CLSA is also set to be among the IPO’s underwriters.
Hua is developing therapies for diabetes and central nervous system (CNS)…
